Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

KISQALI

RIBOCICLIB SUCCINATE

Standard Dose
EQ 200MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: N/A Marketing status: Prescription
Summary

Approval overview KISQALI is listed in Drugs@FDA under application 209092 (NDA).

Review priority: N/A Marketing status: Prescription Active ingredient RIBOCICLIB SUCCINATE Form and strength TABLET;ORAL - EQ 200MG BASE Sponsor NOVARTIS Submission history Latest submission status date: 2025-09-16 00:00:00.

Structured Monograph

Clinical summary

Approval overview KISQALI is listed in Drugs@FDA under application 209092 (NDA). Review priority: N/A Marketing status: Prescription Active ingredient RIBOCICLIB SUCCINATE Form and strength TABLET;ORAL - EQ 200MG BASE Sponsor NOVARTIS Submission history Latest submission status date: 2025-09-16 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: N/A

Interaction Notes

  • No interaction notes stored yet.